Sharsti Sandall, PhD

Sharsti has spent the last 11+ years discovering and developing antibody drug conjugates (ADCs) at Pfizer (formerly Seagen).  During her tenure, she has initiated and led the research efforts for many clinical ADCs, with a strong focus on defining parameters for pairing the right target, linker, and payload and broadening the understanding of ADC sensitivity and resistance.  In her current position, she is a Sr. Director in the Oncology Research Group where she oversees the biology research for the Pfizer ADC portfolio. Prior to joining Seagen, Sharsti was a Damon Runyon Postdoctoral Fellow at the Salk Institute for Biological Studies studying the adult tissue stem cell niche.  She earned her BS in Microbiology from California State University, Long Beach and her PhD in Biomedical Sciences from the University of California, San Diego where she uncovered novel insights into mitotic spindle function.  In her spare time, she loves spending time outdoors with her family and dog, especially skiing, boating, running, and attending local Seattle sporting events.